Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Respiratory Distress Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Respiratory Distress Syndrome Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Respiratory Distress Syndrome Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Acute Respiratory Distress Syndrome Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Respiratory Distress Syndrome Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Acute Respiratory Distress Syndrome Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Acute Respiratory Distress Syndrome Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Altor BioSciences
Faron Pharmaceuticals, Ltd.
Ikaria, Inc.
GlaxoSmithKline

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 8
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.6 Treatment and Management Options 11
2.6.1 Referral Pathway 12
2.7 GlobalData Pipeline Report Guidance 12
3 ARDS Therapeutics - Market Characterization 13
3.1 ARDS Therapeutics Market Size (2005-2010) – Global 13
3.2 ARDS Therapeutics Market Forecast (2010-2017) – Global 14
3.3 ARDS Therapeutics Market Size (2005-2010) – The US 15
3.4 ARDS Therapeutics Market Forecast (2010-2017) – The US 16
3.5 ARDS Therapeutics Market Size (2005-2010) – France 17
3.6 ARDS Therapeutics Market Forecast (2010-2017) – France 18
3.7 ARDS Therapeutics Market Size (2005-2010) – Germany 19
3.8 ARDS Therapeutics Market Forecast (2010-2017) – Germany 20
3.9 ARDS Therapeutics Market Size (2005-2010) – Italy 21
3.10 ARDS Therapeutics Market Forecast (2010-2017) – Italy 22
3.11 ARDS Therapeutics Market Size (2005-2010) – Spain 23
3.12 ARDS Therapeutics Market Forecast (2010-2017) – Spain 24
3.13 ARDS Therapeutics Market Size (2005-2010) – The UK 25
3.14 ARDS Therapeutics Market Forecast (2010-2017) – The UK 26
3.15 ARDS Therapeutics Market Size (2005-2010) – Japan 27
3.16 ARDS Therapeutics Market Forecast (2010-2017) – Japan 28
3.17 Drivers and Barriers for the ARDS Therapeutics Market 29
3.17.1 Drivers for the ARDS Therapeutics Market 29
3.17.2 Barriers for the ARDS Therapeutics Market 29
3.18 Opportunity and Unmet Need Analysis 30
3.19 Key Takeaway 30
4 ARDS Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.1.1 Strategic Competitor Assessment 31
4.2 Product Profiles for the Major Marketed Products in the ARDS Therapeutics Market 32
4.2.1 Levaquin (levofloxacin) 32
4.2.2 Nimbex (cisatracurium besylate) 33
4.3 Key Takeaway 33
5 ARDS Therapeutics - Pipeline Assessment 34
5.1 Overview 34
5.2 Strategic Pipeline Assessment 34
5.3 Pipeline by Phases of Development 34
5.3.1 ARDS Therapeutics, Phase III Pipeline 34
5.3.2 ARDS Therapeutics, Phase II Pipeline 35
5.3.3 ARDS Therapeutics, Phase I Pipeline 35
5.3.4 ARDS Market, Discovery and Pre-Clinical Pipeline 35
5.3.5 Technology Trends Analytic Framework 36
5.4 ARDS Therapeutics Market, Clinical Pipeline by Mechanism of Action 38
5.5 Key Takeaway 38
6 ARDS Therapeutics - Clinical Trials Mapping 39
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 39
6.2 Clinical Trials by Phase 40
6.3 Clinical Trials by Trial Status 41
6.4 Prominent Sponsors 42
6.5 Top Companies Participating in ARDS Therapeutics Clinical Trials 44
7 Strategic Assessment 45
7.1 Key Events Impacting the Future Market 45
7.2 ARDS Therapeutics - Implications for Future Market Competition 46
8 ARDS Therapeutics - Future Players 47
8.1 Introduction 47
8.2 Company Profiles 48
8.2.1 Altor BioSciences 48
8.2.2 Faron Pharmaceuticals, Ltd. 49
8.2.3 Ikaria, Inc. 51
8.2.4 GlaxoSmithKline 52
9 ARDS Therapeutics - Licensing and Partnership Deals 55
10 ARDS Therapeutics - Appendix 56
10.1 Market Definitions 56
10.2 Abbreviations 56
10.3 Research Methodology 57
10.3.1 Coverage 57
10.3.2 Secondary Research 57
10.3.3 Forecasting 58
10.3.4 Primary Research 60
10.3.5 Expert Panel Validation 60
10.4 Contact Us 60
10.5 Disclaimer 61
10.6 Bibliography 61"

1.1 List of Tables
Table 1: Lung Pressure In ARDS 6
Table 2: Clinical Disorders Commonly Associated with ARDS 10
Table 3: ARDS Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Table 4: ARDS Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Table 5: ARDS Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Table 6: ARDS Therapeutics Market, The US, Forecasts ($m), 2010–2017 16
Table 7: ARDS Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 8: ARDS Therapeutics Market, France, Forecasts ($m), 2010–2017 18
Table 9: ARDS Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 10: ARDS Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Table 11: ARDS Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 12: ARDS Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Table 13: ARDS Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 14: ARDS Therapeutics Market, Spain, Forecasts ($m), 2010–2017 24
Table 15: ARDS Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Table 16: ARDS Therapeutics Market, The UK, Forecasts ($m), 2010–2017 26
Table 17: ARDS Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 18: ARDS Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Table 19: ARDS Therapeutics, Phase II Pipeline, 2011 35
Table 20: ARDS Therapeutics, Phase I Pipeline, 2011 35
Table 21: ARDS Therapeutics, Preclinical Pipeline, 2011 35
Table 22: ARDS Therapeutics, Clinical Trials by Country, 2011 39
Table 23: ARDS Therapeutics, Clinical Trials by Phase, 2011 40
Table 24: ARDS Therapeutics, Clinical Trials by Status, 2011 41
Table 25: ARDS Therapeutics, Overall Sponsors, 2011 42
Table 26: ARDS Therapeutics, Prominent Sponsors, 2011 43
Table 27: ARDS Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 44
Table 28: Altor BioSciences, Inflammatory and Infectious Diseases, Pipeline, 2011 48
Table 29: Altor BioSciences, ARDS, Pipeline, 2011 48
Table 30: Faron Pharmaceuticals, Inflammatory and Infectious Diseases Pipeline, 2011 49
Table 31: Faron Pharmaceuticals, ARDS Pipeline, 2011 49
Table 32: Faron Pharmaceuticals, Deals, 2009-2011 50
Table 33: Ikaria, Inc., CNS Pipeline, 2011 51
Table 34: Ikaria, Inc., ARDS pipeline, 2011 51
Table 35: Ikaria, Inc., Deals, 2009-2011 51
Table 36: GlaxoSmithKline, Respiratory Diseases Pipeline, 2011 53
Table 37: GlaxoSmithKline, ARDS pipeline, 2011 54
Table 38: GlaxoSmithKline, Deals, 2009-2011 54
Table 39: ARDS Therapeutics, Deals, 2009-2011 55"

1.2 List of Figures
Figure 1: ARDS Pulmonary Pressure 6
Figure 2: ARDS Affected Lung With Enlarged Alveoli 7
Figure 3: Time Course for the Development and Resolution of ARDS 9
Figure 4: Lung Infected with ARDS 9
Figure 5: ARDS, Treatment Patterns 11
Figure 6: ARDS, Referral Pathway 12
Figure 7: ARDS Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 8: ARDS Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Figure 9: ARDS Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Figure 10: ARDS Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Figure 11: ARDS Therapeutics Market, France, Revenue ($m), 2005–2010 17
Figure 12: ARDS Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 13: ARDS Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 14: ARDS Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Figure 15: ARDS Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 16: ARDS Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 17: ARDS Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 18: ARDS Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 19: ARDS Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Figure 20: ARDS Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Figure 21: ARDS Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 22: ARDS Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 23: Opportunity and Unmet Need in the ARDS Therapeutics Market, 2010 30
Figure 24: ARDS Therapeutics, Strategic Competitor Assessment, 2010 31
Figure 25: ARDS Therapeutics, Pipeline by Phase of Development, 2011 34
Figure 26: ARDS Therapeutics, Technology Trends Analytics Framework, 2011 36
Figure 27: ARDS Therapeutics, Technology Trends Analytics Framework, Description, 2011 37
Figure 28: ARDS Therapeutics, Pipeline by Mechanism of Action (%), 2011 38
Figure 29: ARDS Therapeutics, Clinical Trials by Country, 2011 39
Figure 30: ARDS Therapeutics, Clinical Trials by Phase (%), 2011 40
Figure 31: ARDS Therapeutics, Clinical Trials by Status (%), 2011 41
Figure 32: ARDS Therapeutics, Overall Sponsors (%), 2011 42
Figure 33: ARDS Therapeutics, Prominent Sponsors (%), 2011 43
Figure 34: ARDS Therapeutics, Global,  Clinical Trials by Top Companies , 2011 44
Figure 35: ARDS Therapeutics Market, Drivers and Barriers, 2011 45
Figure 36: Implications for Future Market Competition in the ARDS Market, 2011 46
Figure 37: ARDS Therapeutics Market, Pipeline by Company, 2010 47
Figure 38: GlobalData Market Forecasting Model 59